InvestorsHub Logo
Followers 21
Posts 2539
Boards Moderated 0
Alias Born 12/07/2013

Re: Tatsumaki post# 389973

Tuesday, 10/04/2022 12:45:10 PM

Tuesday, October 04, 2022 12:45:10 PM

Post# of 425930
This is very true but you have to realize it was sold by a company that understood marketing and physicians. First off they never called it "Fish oil." Doctors thought it was a manufactured pharmaceutical product. They also never advised physicians that it raised LDL by 49%. They marketed to their strong point of reducing trigs suggesting, as was the existing knowledge at that time, that it would reduce CAD.

So now you have to ask yourself GSK had no outcomes study, Eunucha does, and yet EUnucha is impotent ( pun intended this time... ROFL !) This all boils down to total incompetence.

Eunucha ( formerly AMRN ) will go down in the business books as the prime example of how incompetent management can destroy a blockbuster product

SHort the stock after this blip ...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News